Alder BioPharmaceuticals Inc. | Key People and Executives
Robert W. Azelby
President, Chief Executive Officer & Director
Paul B. Cleveland
Director
Jeremy Charles Green
Independent Director
Wendy L. Yarno
Independent Director
Paul R. Carter
Independent Director
Clay B. Siegall
Independent Director
Alan B. Montgomery
Independent Director
Deepa R. Pakianathan
Independent Director
Heather Elizabeth Preston
Independent Director
Robert W. Azelby
President, Chief Executive Officer & Director
Erin Lavelle
Chief Operating Officer
Eric G. Carter
Chief Medical Officer
John A. Latham
Chief Scientific Officer
Randal A. Hassler
Executive Vice President-Pharmaceutical Operations
Roger K. Cady
Vice President-Neurology
Elisabeth A. Sandoval
Chief Commercial Officer & EVP-Corporate Strategy
Jeffrey T. L. Smith
Managing Director
Annette Vahratian
Senior Vice President-Quality
Paul B. Cleveland
Director
Larry Benedict
Chief Accounting Officer & Executive VP
Ashwin Agarwal
Vice President-Corporate Strategy
Heather Malcolm
Vice President-Human Resources
James B. Bucher
Senior Vice President & General Counsel
Jeremy Charles Green
Independent Director
Wendy L. Yarno
Independent Director
Paul R. Carter
Independent Director
Clay B. Siegall
Independent Director
Alan Bruce Montgomery
Independent Director
Deepa R. Pakianathan
Independent Director
Heather Elizabeth Preston
Independent Director
| Address |
11804 North Creek Parkway South
Bothell Washington 98011
United States
|
|
Employees
|
- |
| Website |
http://www.alderbio.com |
| Updated |
07/08/2019 |
| Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. |
